Product Information
IVABRADINE HCL 7.5 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.6400 per EA under NDC 70710147206. Its NADAC has been published 102 times since Oct 23, 2024.
FDA first approved this application on Nov 29, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
7.5 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710147206
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IVABRADINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213442FDA Approved
11/29/2023
TE Code
AB
On Market Since
7/2/2024
Pharmacological Classes
Price Statistics
The NADAC for IVABRADINE HCL 7.5 MG TABLET has been published 102 times since Oct 23, 2024, and over the history we have for it it has declined 89.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6400 per EA |
|---|---|
| All-time high | $6.2147 (Nov 13, 2024) |
| All-time low | $0.6400 (Sep 23, 2026) |
| 52-week high | $2.6031 |
| 52-week low | $0.6400 |
| Median price | $2.6031 |
| Average price | $2.6673 |
| Largest weekly change | -25.7% (Feb 18, 2026) |
| Weeks tracked | 102 |
| Tracking since | Oct 23, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ivabradine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IVABRADINE HCL 7.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for IVABRADINE HCL 7.5 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.6400 per EA (NDC 70710147206), effective Sep 30, 2026.
How has the price of IVABRADINE HCL 7.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for IVABRADINE HCL 7.5 MG TABLET has declined 89.7%. It has been tracked across 102 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for IVABRADINE HCL 7.5 MG TABLET?
Since Oct 23, 2024, the NADAC for IVABRADINE HCL 7.5 MG TABLET has ranged from a low of $0.6400 (Sep 23, 2026) to a high of $6.2147 (Nov 13, 2024), with a median of $2.6031 per EA.
Are there cheaper alternatives to IVABRADINE HCL 7.5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as IVABRADINE HCL 7.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures IVABRADINE HCL 7.5 MG TABLET?
IVABRADINE HCL 7.5 MG TABLET (NDC 70710147206) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.